非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析*

doi:10.3969/j.issn.1672-5069.2020.02.004

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (2): 163-166.doi: 10.3969/j.issn.1672-5069.2020.02.004

非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*

张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿

201508 上海市复旦大学附属上海市公共卫生临床中心肝胆外科

收稿日期:2019-04-19 出版日期:2020-03-10 发布日期:2020-04-20
通讯作者: 黄杨卿,E-mail:eric_huangyq@163.com
作者简介:张猛,男,29岁,医学硕士,主治医师。主要从事肝脏疾病诊断与治疗学研究。E-mail:zhangmeng152569@126.com
基金资助:
上海市卫生和计划生育委员会科研项目(编号:201840128)

Up-regulation of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases

Zhang Meng, Chen Yi, Liu Jiao, et al

Department of Hepatobiliary Surgery , Public Health Clinical Center, Fudan University , Shanghai 201508, China

Received:2019-04-19 Online:2020-03-10 Published:2020-04-20

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)小鼠肝组织脂质代谢相关基因水平变化。方法采用高脂饲料喂养20小鼠,构建小鼠NAFLD动物模型,观察小鼠肝组织病理学变化,检测血清总胆固醇(TCH) 和甘油三酯(TG)含量,采用RT-PCR法检测小鼠肝组织胆固醇调节元件结合蛋白(SREBPs)、乙酰辅酶A羧化酶(ACC)和脂肪酸合成酶(fatty acid synthase, FAS)基因变化。结果 10只NAFLD模型小鼠肝细胞排列不整齐,肝细胞内出现大小不等的脂滴;NAFLD模型小鼠血清TG和TCH水平分别为(0.63±0.13)mmol/L和(7.23±0.7)mmol/L,显著高于10只对照组[(0.28±0.06)mmol/L和(2.78±0.6)mmol/L,P<0.001];在实验24 w末,NAFLD组小鼠肝组织FAS 和SREBP-1 mRNA水平分别为(3.9±1.1)和(1.8±0.7),对照组则分别为【(1.0±0.3)和(1.0±0.4),FAS: t = 6.231, P<0.001; SREBP-1: t =2.431, P =0.035】,差异显著,而NAFLD组小鼠肝组织ACC mRNA水平为(1.2±0.5),与对照组【(1.0±0.4), t=0.765, P=0.462】比,无显著差异。结论 NAFLD模型小鼠肝组织与脂质代谢相关基因显著上调,为进一步研究NAFLD的发生发展机制奠定了基础。

关键词: 非酒精性脂肪性肝病, 脂质代谢, 脂肪酸合成酶, 胆固醇调节元件结合蛋白, 小鼠

Abstract: Objective The aim of this experiment was to investigate the changes of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases (NAFLD). Methods A NAFLD model was established in ten mice by feeding high-fat diet. The histopathological changes of the liver tissues were observed. Blood total cholesterol (TCH) and triglycerides (TG) levels were detected, and sterol regulatory element-binding proteins (SREBPs), acetyl coenzyme carboxylase (ACC) and fatty acid synthase (FAS) mRNA were detected by reverse transcription-polymerase chain reaction. Results The steatosis of liver cells was found in mice in NAFLD model group; blood TG and TCH levels in NAFLD model group were (0.63±0.13) mmol/L and (7.23±0.7) mmol/L, significantly higher than [(0.28± 0.06) mmol/L and (2.78±0.6) mmol/L, P<0.001] in ten mice in the control; at the end of 24 w experiment, hepatic FAS and SREBP-1 mRNA in NAFLD mice were (3.9±1.1) and (1.8±0.7), significantly higher than 【(1.0±0.3) and (1.0±0.4), FAS: t = 6.231, P<0.001; SREBP-1: t = 2.431, P =0.035】, while the ACC mRNA was (1.2±0.5), not significantly different as compared to 【(1.0±0.4), t = 0.765, P =0.462】 in the control. Conclusion The lipid metabolism related genes in liver tissue of mice with NAFLD are significantly up-regulated, which might play a pivotal role in the pathogenesis of NAFLD.

Key words: Nonalcoholic fatty liver, Lipid metabolism, Sterol regulatory element-binding proteins, Acetyl coenzyme carboxylase, Fatty acid synthase, Mice

张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿. 非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 163-166.

Zhang Meng, Chen Yi, Liu Jiao, et al. Up-regulation of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2020, 23(2): 163-166.

参考文献

[1] Weiβ J, Rau M , Geier A . Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int, 2014, 111(26):447.
[2] 田军伟,肖远力,王艳超. 应用血清TG/HDL-C比值早期诊断非酒精性脂肪性肝病患者临床价值探讨. 实用肝脏病杂志,2017,20(4):416-419.
[3] Højland Ipsen D, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci,2018,75(18): 3313-3327.
[4] Mohamed A, Lounis, Karl F, et al. Oleate activates SREBP-1 signaling activity in SCD1- deficient hepatocytes. Physiol Endocrinol Metab, 2017, 313(6): 710-720.
[5] Ren TT, Zhu JJ, Zhu LL, et al . The combination of blueberry juice and probiotics ameliorate non-alcoholic steatohepatitis by affecting SREBP-1c/PNPLA-3 pathway via PPAR-α. Nutrients,2017, 9(3): 198.
[6] 池肇春.非酒精性脂肪性肝炎肝硬化发病机制研究进展与展望. 实用肝脏病杂志,2018,21(2):166-169.
[7] Zhang X, Ji XT, Wang Q, et al . New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell, 2018, 9(2): 164-177.
[8] Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol, 2014, 20(26): 8364-8376.
[9] He Q, Li JK, Li F, et al . Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. World J Gastroenterol, 2015,21(7): 2058-2066.
[10] Sohair M, Raga B, Sary KH, et al . Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. Lipids Health Dis, 2015, 14: 83.
[11] Meng Y, Liu Y, Fang NN, et al . Hepatoprotective effects of cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. Pharm Biol,2019, 57(1): 98-104.
[12] Miyata S, Inoue J, Shimizu M, et al. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) activation. Biol Chem, 2015,290(33): 20565-20579.
[13] Kuan YC, Hashidume T, Shibata T, et al. Heat shock protein 90 modulates lipid homeostasis by regulating the stability and function of sterol regulatory element-binding protein (SREBP) and SREBP cleavage-activating protein. Biol Chem, 2017, 292(7): 3016-3028.
[14] Jelenik T , Kaul K , Séquaris G, et al. Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver. Diabetes, 2017, 66(8):2241.
[15] Birgit K , Sonja H , Sylvia J , et al. Inactivation of SREBP-1a phosphorylation prevents fatty liver disease in mice: identification of related signaling pathways by gene expression profiles in liver and proteomes of peroxisomes. Int J Mol Sci, 2018, 19(4):980.
[16] Ito M, Nagasawa M, Omae N, et al. A novel JNK2/SREBP-1c pathway involved in insulin-induced fatty acid synthesis in human adipocytes. Lipid Res, 2013, 54(6): 1531-1540.
[17] Torres JL, Novo-Veleiro I, Manzanedo L, et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol, 2018, 24(36): 4104-4118.
[18] Shu ZP, Gao Y, Zhang GP, et al. A functional interaction between Hippo‐YAP signalling and SREBPs mediates hepatic steatosis in diabetic mice. Cell Mol Med, 2019, 23(5): 3616-3628.
[19] Wang CM, Yuan RS, Zhuang WY, et al. Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice. Lipids Health Dis, 2016, 15: 195.
[20] Shen L, Cui AF, Xue Y, et al. Hepatic differentiated embryo-chondrocyte expressed gene 1 inhibits sterol regulatory element-binding protein-1c expression and alleviates fatty liver phenotype. Biol Chem, 2014, 289(34): 23332-23342.

非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*

Up-regulation of lipid metabolism related genes in liver tissues of mice with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.
[2]	叶晓贤, 杨丽, 雷丽. 血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 199-202.
[3]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[4]	刘继国, 窦翠云, 程广玲. NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*[J]. 实用肝脏病杂志, 2020, 23(2): 207-210.
[5]	曾震军, 李墨航. 血清学指标和脂肪肝指数诊断非酒精性脂肪性肝病价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 211-214.
[6]	王丽娟, 朱兵兵, 胡敏华, 杨丽, 石莉红, 胡健薇. 匹伐他汀与阿托伐他汀治疗非酒精性脂肪性肝病患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(2): 215-218.
[7]	任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.
[8]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[9]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[10]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[11]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[12]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[13]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[14]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[15]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.